Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

NCT ID: NCT05007418

Last Updated: 2023-01-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-01
• Study Completion Date: 2026-02-28

Brief Summary

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

Detailed Description

This is a phase 1b, open-label, multicenter, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

The study will determine the MTD and RP2D, assessing safety and preliminary efficacy using a conventional 3+3 study design with two design stages, an ascending dose stage followed by an expansion study.

Patients will be enrolled sequentially within each cohort and between cohorts during the dose escalation portion of the study with the staggered intervals of at least 28 days. Only one patient will be allowed to receive study treatment at any time through the end of the staggering period before the next subject may begin study treatment.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

STI-1492

Four dosing cohorts will be evaluated: Cohort 1 (1 × 10\^5 donor DAR-T cells/kg); Cohort 2 (5 × 10\^5 donor DAR-T cells/kg); Cohort 3 (1 × 10\^6 donor DAR-T cells/kg); Cohort 4 (3 × 10\^6 donor DAR-T cells/kg) where STI-1492 will be administered intravenously once.

Group Type: EXPERIMENTAL

STI-1492

Intervention Type: BIOLOGICAL

Anti-CD38 A2 KOKI DAR T cells

Interventions

STI-1492

Anti-CD38 A2 KOKI DAR T cells

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments.
• Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample
• Evidence of cell membrane CD38 expression as determined by immunohistochemistry (IHC) analysis ofbone marrow biopsy or extramedullary plasmacytoma
• Pulse oximetry ≥ 92% on room air
• Have a life expectancy ≥ 12 weeks
• Be willing and able to comply with the study schedule and all study requirements
• Willing to follow contraception guidelines

Exclusion Criteria

• Previous treatment with any systemic therapy for multiple myeloma within 14 days prior to start of study dose
• Treatment with any cellular therapy within 8 weeks prior to start of study dose
• Have any unresolved toxicity ≥ Grade 2 from previous anticancer therapies
• A history of brain metastasis or spinal cord compression
• Has an ECOG performance status (PS) ≥ 3
• Has received allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months, has active graft-versus-host disease (GvHD) following transplant, or is currently receiving immunosuppressive therapy following transplant
• Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening unless resulting from underlying RRMM
• Has any clinically significant elevated baseline lab results for serum creatinine, AST or β2 microglobulin
• Abnormal INR or aPTT, unless on a stable dose of an anticoagulant
• Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C
• Is currently pregnant or breast feeding or planning on either during the study.
• Has an active bacterial, viral, or fungal infection
• Has active plasma cell leukemia
• Has extramedullary plasmacytoma(s)
• Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation
• Has left ventricular ejection fraction (LVEF) < 40%
• Has second primary malignancies (SPMs) in addition to multiple myeloma if the SPM has required therapy within the last 3 years or is not in complete remission
• Has any additional clinical history of the CNS or cardiovascular disease that would place the patient at an unacceptable risk if the patient participates in the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sorrento Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mike Royal, MD

Role: STUDY_DIRECTOR

Sorrento Therapeutics, Inc.

Locations

UC Irvine

Orange, California, United States

Site Status: NOT_YET_RECRUITING

UC Davis

Sacramento, California, United States

Site Status: NOT_YET_RECRUITING

University of Oklahoma

Oklahoma City, Oklahoma, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Mike Royal, MD

Role: CONTACT

mroyal@sorrentotherapeutics.com

(858)203-4100 ext. 4146

Facility Contacts

Blake Johnson

Role: primary

blakej@hs.uci.edu

714-456-3476

Erika Crawford

Role: primary

encrawford@ucdavis.edu

916-501-9393

Silas Day

Role: primary

silas-day@ouhsc.edu

405-271-8001

Other Identifiers

38DART-RRMM-101

Identifier Type: -

Identifier Source: org_study_id